Cipla Ltd
NSE:CIPLA
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 174.4
1 683
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CIPLA stock under the Base Case scenario is 1 173.46 INR. Compared to the current market price of 1 486.5 INR, Cipla Ltd is Overvalued by 21%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Cipla Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CIPLA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Cipla Ltd. stands as a prominent player in the global pharmaceutical landscape, rooted in its founding vision of accessible healthcare for all. Established in 1935 in India, the company has evolved from its initial focus on producing affordable medicines to becoming a leading provider of generic and specialty pharmaceuticals, over-the-counter products, and active pharmaceutical ingredients (APIs). With a strong commitment to innovation, Cipla allocates a significant portion of its resources to research and development, leading to a robust pipeline of patented and life-saving treatments, particularly in the fields of respiratory, HIV/AIDS, and oncology therapies. This focus on both global mar...
Cipla Ltd. stands as a prominent player in the global pharmaceutical landscape, rooted in its founding vision of accessible healthcare for all. Established in 1935 in India, the company has evolved from its initial focus on producing affordable medicines to becoming a leading provider of generic and specialty pharmaceuticals, over-the-counter products, and active pharmaceutical ingredients (APIs). With a strong commitment to innovation, Cipla allocates a significant portion of its resources to research and development, leading to a robust pipeline of patented and life-saving treatments, particularly in the fields of respiratory, HIV/AIDS, and oncology therapies. This focus on both global markets and local needs has positioned Cipla not only as a trusted brand in India but also as a key player in over 80 countries worldwide.
For investors, Cipla represents a compelling opportunity due to its strategic initiatives aimed at sustaining growth amidst challenging market dynamics. The company's impressive financial performance, characterized by steady revenue growth and healthy margins, underscores its operational efficiency and market-leading position. Cipla’s proactive approach to collaborations, licensing agreements, and technological advancements indicates a future that embraces pharmaceutical innovations while maintaining cost-effective solutions. Furthermore, its commitment to sustainability and ethical practices resonates well in today's socially conscious investing landscape. As healthcare demands continue to rise globally, Cipla's mission to enhance access to vital medications stands to benefit both patients and shareholders alike.
Cipla Ltd. is a global pharmaceutical company based in India, with a strong presence in the healthcare sector. The company operates through several core business segments, which primarily include:
-
Pharmaceuticals:
- Generic Medicines: Cipla is widely known for its generic pharmaceuticals, offering a range of therapeutics across various disease segments. This includes treatments for respiratory, cardiovascular, and infectious diseases.
-
Chronic and Acute Therapy:
- Chronic Therapy: Products focused on long-term conditions such as diabetes, cardiovascular diseases, and respiratory ailments.
- Acute Therapy: Medications that address short-term medical conditions, contributing to immediate healthcare needs.
-
Specialty Drugs:
- Cipla has been expanding its portfolio in specialty therapies, which includes biologics and biosimilars, targeting complex diseases like oncology and HIV/AIDS.
-
Consumer Health:
- This segment includes over-the-counter (OTC) products and wellness solutions that address health needs in a non-prescription format, focusing on areas such as nutrition, personal care, and preventive health.
-
Biologics:
- Cipla is increasingly investing in biologics, including monoclonal antibodies and other advanced therapies to treat complex disease conditions.
-
Animal Health:
- The animal health segment involves the development and production of veterinary products, addressing needs in the livestock and pet sectors.
-
Regulated Markets:
- The company also focuses on exports to highly regulated markets such as the United States, Europe, and Australia, complying with stringent quality standards and regulations.
-
Emerging Markets:
- Cipla has a significant presence in emerging markets across Asia, Africa, and Latin America, catering to local healthcare needs with tailored products.
-
Research and Development:
- Continuous investment in R&D to innovate and improve product offerings, developing new formulations, drug delivery systems, and improving efficacy and safety profiles.
Cipla’s diverse product portfolio and strategic focus on research and development have positioned it as a key player in the global pharmaceutical landscape, addressing a wide range of health conditions and expanding access to quality medicines.
Cipla Ltd, a prominent player in the pharmaceutical industry, possesses several unique competitive advantages that distinguish it from its rivals:
-
Strong Brand Equity: Cipla has established a robust brand reputation over decades, known for its quality and reliability, especially in the generic medication sector.
-
Diverse Product Portfolio: The company offers an extensive range of pharmaceutical products, including generics, branded formulations, biosimilars, and specialty medications across various therapeutic areas. This diversification helps mitigate risks associated with dependency on any single product line.
-
Research and Development (R&D) Focus: Cipla invests significantly in R&D, allowing it to innovate and develop new drugs, including complex generics. The ability to produce high-quality formulations and specialized medications gives it an edge in competitive markets.
-
Global Presence and Market Penetration: Cipla has a strong international footprint, selling products in over 150 countries. This geographical diversification helps offset risks related to regulatory changes or market fluctuations in any single region.
-
Cost Efficiency and Manufacturing Capabilities: The company benefits from large-scale manufacturing facilities that leverage economies of scale. Its ability to maintain lower production costs while ensuring high-quality standards offers a competitive pricing advantage.
-
Strategic Partnerships and Alliances: Cipla collaborates with various international pharmaceutical companies and organizations, enhancing its research capabilities and market access. These partnerships often lead to co-development of innovative therapies.
-
Robust Regulatory Compliance: With a strong compliance framework, Cipla adheres to strict quality standards and regulations in various markets, thus ensuring product integrity and safety, which bolsters customer trust and loyalty.
-
Focus on Emerging Markets: Cipla’s strategy includes expanding its presence in emerging markets where demand for affordable healthcare is rising. This positions it to capitalize on growth opportunities in these regions.
-
Patient-Centric Approach: Cipla emphasizes making healthcare accessible, particularly in developing countries. This commitment to affordability aligns with growing global demands for cost-effective treatment, enhancing its brand loyalty and market share.
-
Innovation in Delivery Systems: Cipla has developed unique drug delivery systems and formulations that cater to patient needs, helping differentiate its products in the competitive landscape.
These competitive advantages enable Cipla to sustain its market position, drive growth, and navigate challenges within the pharmaceutical industry effectively.
Cipla Ltd, a major player in the pharmaceutical industry, faces several risks and challenges in the near future, including:
1. Regulatory Risks:
- Compliance with Regulations: Adhering to stringent regulatory standards in different markets can be challenging. Changes in regulations may require additional investments in compliance and quality control.
- Approval Delays: The time taken for product approval by agencies like the FDA can impact the launch of new drugs.
2. Competition:
- Generic Drug Market: Intense competition from generic drug manufacturers can squeeze profit margins.
- Innovative Pharmaceuticals: There is increasing competition from companies developing innovative, patent-protected drugs which can lead to market share losses for Cipla.
3. Market Dynamics:
- Price Erosion: Ongoing price erosion in the generic market can impact revenues, especially in developed markets.
- Foreign Exchange Fluctuations: As a company with a significant export portfolio, exchange rate volatility can impact profitability.
4. R&D Challenges:
- Investment in Innovation: Continuous investment in R&D is critical for long-term growth, but it also involves risks related to unsuccessful drug development.
- Pipeline Management: Managing a diverse pipeline while ensuring successful outcomes can be complex and resource-intensive.
5. Supply Chain Disruptions:
- Global Supply Chain Risks: Events such as geopolitical tensions, pandemics, or natural disasters can disrupt the supply chain, affecting production and distribution.
6. Patent Expirations:
- Loss of Exclusivity: The expiration of patents on key products can lead to a decline in revenues from these drugs, necessitating a stronger focus on new product development.
7. Talent Retention:
- Attracting Skilled Workforce: The pharmaceutical sector requires highly skilled professionals. The ability to attract and retain talent in R&D and other critical areas can be a challenge.
8. Strategic Partnerships:
- Dependence on Collaborations: Cipla may rely on strategic partnerships for certain products or market access. The success of these ventures can significantly influence its performance.
9. Environmental and Social Responsibility:
- Sustainability Goals: Increasing pressure to meet sustainability and ethical standards in business operations and supply chains can present challenges.
10. Market Sentiment:
- Investor Relations: Changes in market sentiment or negative news can impact stock performance and the company’s ability to raise capital.
Conclusion:
Navigating these risks requires Cipla Ltd to have robust risk management strategies, continuous innovation, and adaptive planning to sustain its competitive edge in the evolving pharmaceutical landscape.
Revenue & Expenses Breakdown
Cipla Ltd
Balance Sheet Decomposition
Cipla Ltd
Current Assets | 209.5B |
Cash & Short-Term Investments | 87.1B |
Receivables | 55.9B |
Other Current Assets | 66.5B |
Non-Current Assets | 137.1B |
Long-Term Investments | 12.2B |
PP&E | 62.2B |
Intangibles | 51.1B |
Other Non-Current Assets | 11.6B |
Current Liabilities | 54.5B |
Accounts Payable | 26.8B |
Other Current Liabilities | 27.8B |
Non-Current Liabilities | 8.4B |
Long-Term Debt | 2.2B |
Other Non-Current Liabilities | 6.2B |
Earnings Waterfall
Cipla Ltd
Revenue
|
265.1B
INR
|
Cost of Revenue
|
-87.5B
INR
|
Gross Profit
|
177.7B
INR
|
Operating Expenses
|
-121.4B
INR
|
Operating Income
|
56.2B
INR
|
Other Expenses
|
-11.5B
INR
|
Net Income
|
44.8B
INR
|
Free Cash Flow Analysis
Cipla Ltd
INR | |
Free Cash Flow | INR |
In Q2 FY '25, Cipla reported record EBITDA margins at 26.7%, reflecting strong profitability amid a 9% revenue growth to INR 7,051 crores. The slower growth in their One India business was due to changes in the seasonal pattern, especially in acute therapies, with anti-infectives growing only 4.9%. However, chronic therapies like respiratory and cardiac grew by 9% and 11%, respectively. For FY '25, Cipla maintains an EBITDA margin guidance of 24.5% to 25.5%. Although they face temporary supply issues in the Lanreotide franchise, recovery is expected by Q4 FY '25. The company continues to invest in expansion and strategically develop key markets.
What is Earnings Call?
CIPLA Profitability Score
Profitability Due Diligence
Cipla Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Cipla Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
CIPLA Solvency Score
Solvency Due Diligence
Cipla Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Cipla Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CIPLA Price Targets Summary
Cipla Ltd
According to Wall Street analysts, the average 1-year price target for CIPLA is 1 658.23 INR with a low forecast of 1 216.04 INR and a high forecast of 2 058 INR.
Dividends
Current shareholder yield for CIPLA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CIPLA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. The company is headquartered in Mumbai, Maharashtra and currently employs 21,891 full-time employees. The Company’s segments include Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The firm's geographical segments include India, the United States, South Africa and Rest of the World. The firm has its network of manufacturing, trading and other incidental operations in India and International markets. The firm has approximately 46 manufacturing sites.
Contact
IPO
Employees
Officers
The intrinsic value of one CIPLA stock under the Base Case scenario is 1 173.46 INR.
Compared to the current market price of 1 486.5 INR, Cipla Ltd is Overvalued by 21%.